Ipilimumab with fotemustine in metastatic melanoma

摘要

Ipilimumab-an antibody against cytotoxic T-lympho-cyte-associated protein 4-was the first systemic treatment in unresectable metastatic melanoma to be proven to extend overall survival. No previous phase 3 trial had shown any significant survival benefit for systemic treatments in melanoma. Two phase 3 clinical trials (one comparing ipilimumab with gplOO vaccination3 and one ipilimumab plus dacarbazine versus dacarbazine alone4) showed a significant improvement of 10% in overall survival after 2-4 years. In these two trials, different doses of 3 and 10 mg/kg were used. 3 mg/kg ipilimumab every 3 weeks for four treatment cycles has been approved in Europe and the USA for treatment of unresectable metastatic melanoma.